Ocrevus Zunovo

UNIISPLATC L04AG

Last synced from FDA National Drug Code directory (United States) on June 3, 2026

Identification

ManufacturerGenentech, Inc.

CountryUS (United States)

ATC codeL04AG

Dispensing—

ReimbursedNo

SourceFDA National Drug Code directory (United States)

Last synced6/3/2026

Packs · 2

ndc11
5024255401
1 VIAL, SINGLE-USE in 1 CARTON (50242-554-01) / 23 mL in 1 VIAL, SINGLE-USE
ndc11
5024255486
1 VIAL, SINGLE-USE in 1 CARTON (50242-554-86) / 23 mL in 1 VIAL, SINGLE-USE

Annotations

UNII (FDA Substance ID)

743QUY4VD8

HYALURONIDASE (HUMAN RECOMBINANT)

RxCUI 1300478

DailyMed SPL labels

1 version tracked

Raw payload (JSON)

{
  "unii": {
    "unii": "743QUY4VD8",
    "rxcui": "1300478",
    "inchikey": null,
    "display_name": "HYALURONIDASE (HUMAN RECOMBINANT)",
    "substance_type": "protein",
    "ingredient_type": "INGREDIENT SUBSTANCE"
  },
  "route": "SUBCUTANEOUS",
  "spl_meta": {
    "9da42362-3bb5-4b83-b4bb-b59fd4e55f0d": {
      "match": "brand_token",
      "title": "OCREVUS (OCRELIZUMAB) INJECTION [GENENTECH, INC.]",
      "spl_version": "24",
      "published_date": "2026-05-20"
    }
  },
  "productid": "50242-554_30b58964-86ef-483b-9a38-7f9fec14647c",
  "productndc": "50242-554",
  "dosage_form": "INJECTION, SOLUTION",
  "dea_schedule": null,
  "product_type": "HUMAN PRESCRIPTION DRUG",
  "substance_name": "HYALURONIDASE (HUMAN RECOMBINANT); OCRELIZUMAB",
  "proprietary_name": "Ocrevus Zunovo",
  "active_ingred_unit": "U/23mL; mg/23mL",
  "application_number": "BLA761371",
  "marketing_category": "BLA",
  "nonproprietary_name": "ocrelizumab and hyaluronidase",
  "start_marketing_date": "20240913",
  "active_numerator_strength": "23000; 920"
}

Related drugs

Other records sharing ATC code L04AG.

Access this data programmatically

Query Ocrevus Zunovo and 610,000+ other drug records through a single REST API — with a last_synced_at provenance stamp on every response. Free tier includes 100 requests/day.

Get a free API key Read the API docs